Continuous intrathecal fluid infusions elevate nerve growth factor levels and prevent functional deficits after spinal cord ischemia.
Continuous intracerebroventricular or intrathecal infusions of neurotrophic factors have been reported to prevent neuronal degeneration, stimulate axonal sprouting and ameliorate behavioral deficits in various models of CNS injury and aging. In the present study, the ability of intrathecal infusions of recombinant human nerve growth factor (NGF) to reduce functional deficits following spinal cord ischemia was investigated. Adult rabbits underwent intrathecal cannulation and continuous infusions of either 300 microg/ml recombinant human NGF or artificial CSF (vehicle) at a rate of 143 microl/day for 7 days prior to induction of spinal cord ischemia. Continuous infusions were maintained after induction of ischemia. Four days later, both NGF-treated and vehicle-infused subjects showed a significant amelioration of functional motor deficits compared to lesioned, non-infused subjects (P<0.05). The average duration of tolerated ischemia increased from 23.4+/-1.8 min in lesioned, non-infused subjects to 35.5+/-3.1 min in lesioned, artificial CSF-infused subjects and 35.6+/-4.7 min in NGF-infused subjects (mean+/-S.E.M.). Significantly elevated NGF protein levels were attained within the spinal cords of both NGF-treated subjects and artificial CSF-infused subjects, although levels were substantially higher in NGF-treated subjects (9.8+/-3.8 ng/g in NGF-infused vs. 2.0+/-0.4 ng/g in vehicle-infused and only 0.4+/-0.2 ng/g in lesioned, non-infused animals). These findings indicate that the process of intrathecal cannulation and fluid infusion elicits alterations in the spinal cord environment that are neuroprotective, including spontaneous elevations in NGF levels.
Bowes
M
M
Departments of Neurosciences, University of California, San Diego, La Jolla, CA 92093-0626, USA.
Tuszynski
M H
MH
Conner
J
J
Zivin
J A
JA
D000818:Animals; D015918:Infusion Pumps, Implantable; D007278:Injections, Spinal; D008297:Male; D020932:Nerve Growth Factor / Q000008:administration & dosage* / Q000032:analysis; D018696:Neuroprotective Agents / Q000008:administration & dosage; D010264:Paraplegia / Q000188:drug therapy*; D011817:Rabbits; D011994:Recombinant Proteins / Q000008:administration & dosage; D020760:Spinal Cord Ischemia / Q000188:drug therapy*
D018696:Neuroprotective Agents; D011994:Recombinant Proteins; D020932:Nerve Growth Factor